FYARRO
DEAD

Serial Number

98195404

Owner

AADi Bioscience, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Sep 25, 2023

Add to watchlist:

No watchlists yet
View on USPTO

FYARRO Trademark

Serial Number: 98195404

FYARRO is a trademark filed by AADi Bioscience, Inc. on September 25, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

AADi Bioscience, Inc. (13 trademarks)

1343 Luna Vista Dr
Pacific Palisades, CA 90272

Entity Type: 03

Trademark Details

Filing Date

September 25, 2023

Registration Date

Not Registered

Published for Opposition

June 25, 2024

Goods & Services

Pharmaceutical preparations for the treatment and prevention of cardiovascular disease, epilepsy, mitochondrial disease, central nervous system disease, infectious disease, and acute respiratory disease; vaccine preparations; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in in pediatric, geriatric, emergency, family, and psychiatry; pharmaceutical preparations for the treatment of infectious and hereditary diseases

Medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, research and design services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; pharmaceutical research for use in pediatric, geriatric, emergency, family, and preventative medicine; pharmaceutical research for the treatment of infectious, deficiency, hereditary, and physiological diseases

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Sep 22, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Sep 22, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 4, 2025 EXRA
SOU EXTENSION 1 GRANTED
Feb 4, 2025 EX1G
SOU EXTENSION 1 FILED
Feb 3, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 3, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 20, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 25, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 25, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 5, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 20, 2024 CNSA
ASSIGNED TO EXAMINER
May 16, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 10, 2023 NWOS
NEW APPLICATION ENTERED
Sep 28, 2023 NWAP